Profit, though down, is in line with consesus. Given the uncertainty around board and management changes, I thought Andrew Saker's report was direct and in "plain speak" which imho bodes well being a more shareholder friendly management team.
- Forums
- ASX - By Stock
- Ann: Investor Presentation
Profit, though down, is in line with consesus. Given the...
Featured News
Add OBL (ASX) to my watchlist
(20min delay)
|
|||||
Last
88.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $250.0M |
Open | High | Low | Value | Volume |
88.5¢ | 90.5¢ | 86.5¢ | $60.25K | 68.74K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 12499 | 88.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
94.0¢ | 20000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16902 | 0.865 |
2 | 2397 | 0.860 |
1 | 3800 | 0.820 |
1 | 4980 | 0.815 |
1 | 1100 | 0.805 |
Price($) | Vol. | No. |
---|---|---|
0.940 | 20000 | 1 |
0.950 | 13888 | 3 |
0.980 | 12500 | 1 |
0.985 | 14390 | 1 |
0.990 | 1000 | 1 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
OBL (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online